Introduction {#cti21138-sec-0005}
============

Primary immunodeficiency diseases (PIDs) are disorders associated with defects in the immune system. More than 400 different types of monogenic inherited PIDs are currently recognised; these PIDs affect different immune cells (including T cells, B cells and granulocytes) and the complement system.[^1^](#cti21138-bib-0001){ref-type="ref"}, [^2^](#cti21138-bib-0002){ref-type="ref"}, [^3^](#cti21138-bib-0003){ref-type="ref"} Early diagnosis of PIDs is extremely difficult because these diseases do not have specific characteristic symptoms but instead have diverse clinical manifestations, particularly in early life. A lack of a diagnosis can have considerable adverse effects on patients and their families; such effects can include failure to identify potential treatments, recognise the risk of genetic transmission during subsequent pregnancies, and provide anticipatory guidance and prognostic information.

With progress in gene sequencing technologies, increasing numbers of PIDs are being diagnosed. The emerging dominance of next‐generation sequencing (NGS) has driven a rapid increase in the number of recognised PIDs. In the past 2 years, 64 different genetic defects have been recognised.[^1^](#cti21138-bib-0001){ref-type="ref"}, [^2^](#cti21138-bib-0002){ref-type="ref"}, [^4^](#cti21138-bib-0004){ref-type="ref"} Whole‐exome sequencing (WES) can enable rapid diagnosis and has been adopted by several laboratories as the method of choice for diagnosing various PIDs.[^5^](#cti21138-bib-0005){ref-type="ref"}, [^6^](#cti21138-bib-0006){ref-type="ref"}, [^7^](#cti21138-bib-0007){ref-type="ref"}, [^8^](#cti21138-bib-0008){ref-type="ref"}, [^9^](#cti21138-bib-0009){ref-type="ref"} For genetically undiagnosed patients with PIDs, NGS has the ability to contribute significantly to the identification of molecular mechanisms.[^10^](#cti21138-bib-0010){ref-type="ref"}

The genetic and phenotypic heterogeneity of PIDs makes timely and accurate diagnosis challenging, hindering the prompt treatment of patients with PIDs. Here, we report the high diagnostic yield of NGS for PIDs in early life infants.

Results {#cti21138-sec-0006}
=======

Clinical characteristics {#cti21138-sec-0007}
------------------------

From November 2015 to April 2018, 2392 patients were enrolled, including 1353 boys and 1039 girls. The enrolment and outcomes of the subjects participating in the study are shown in Figure [1](#cti21138-fig-0001){ref-type="fig"}. The ages of the patients ranged from 6 to 87 days. In all, 1680 (70.23%) patients required intensive care unit (ICU) support; 1773 (74.12%) patients had been diagnosed with infectious diseases, including sepsis, severe pneumonia and purulent meningitis; and 619  (25.88%) patients had no defined infectious disease, but had abnormal routine blood tests, including 102 with white blood cells \< 4000 cells µL^−1^, 433 with white blood cells \> 20 000 cells µL^−1^ and 84 had platelets \< 100 × 10^9^ L^−1^. The baseline characteristics of the patients are shown in Table [1](#cti21138-tbl-0001){ref-type="table"}. Forty‐five patients with PIDs had particular infections, 12 patients had haematological abnormalities, and eight patients had both a particular infection and haematological abnormalities (Table [2](#cti21138-tbl-0002){ref-type="table"}).

![Enrolment and the outcomes of subjects participating in the study. PID, primary immunodeficiency diseases; WBC, white blood cell.](CTI2-9-e1138-g001){#cti21138-fig-0001}

###### 

Baseline characteristics of enrolled patients

   Characteristics                 *N* (%)
  -------------------------------- ---------------
  Sex                              
  Female                           1039 (43.44%)
  Male                             1353 (56.56%)
  Severity of diseases             
  Requiring ICU support            1680 (70.23%)
  Non‐requiring ICU support        712 (29.77%)
  Infectious diseases              
  Types of diseases                
  Sepsis                           863 (36.08%)
  Severe pneumonia                 681 (28.47%)
  Purulent meningitis              96 (4.01%)
  Chronic diarrhoea                82 (3.43%)
  Other infectious disease         51 (2.13%)
  Pathogens                        
  Bacteria                         1035 (58.38%)
  Fungal                           12 (0.68%)
  Virus                            303 (17.09%)
  Others                           15 (0.85%)
  Unclear                          408 (23.01%)
  Abnormal WBC without infection   535 (22.37%)
  Thrombocytopenia                 84 (3.51%)

ICU, intensive care unit; WBC, white blood cell.
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###### 

The number of patients with particular infections or haematological abnormalities in patients with defined genetic defects

  Disease‐causing gene   The number of total patients   The number of patients with particular infections   The number of patients with haematological abnormalities
  ---------------------- ------------------------------ --------------------------------------------------- ----------------------------------------------------------
  *22q11 del*            13                             12                                                  2
  *CHD7*                 3                              3                                                   0
  *WAS*                  4                              3                                                   4
  *ATM*                  3                              3                                                   0
  *ELANE*                3                              2                                                   3
  *IL10RA*               3                              3                                                   0
  *BTK*                  2                              2                                                   0
  *CYBB*                 2                              2                                                   0
  *IL12RB1*              2                              2                                                   0
  *SH2D1A*               2                              1                                                   1
  *CD40LG*               1                              1                                                   0
  *CSF3R*                1                              1                                                   0
  *CYBA*                 1                              1                                                   0
  *IKBKG*                1                              1                                                   0
  *IL2RG*                1                              1                                                   0
  *ITGB2*                1                              1                                                   1
  *LIG4*                 1                              1                                                   0
  *NOD2*                 1                              0                                                   0
  *RAG1*                 1                              1                                                   0
  *STAT1*                1                              1                                                   0
  *STAT3*                1                              0                                                   0
  *STXBP2*               1                              1                                                   0
  *TNFRSF13B*            1                              1                                                   0
  *VPS13B*               1                              1                                                   1
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Identified disease‐causing variants {#cti21138-sec-0008}
-----------------------------------

Approximately 20 000 single nucleotide variants (SNVs) and 10 copy number variations (CNVs) were detected from each patient's original sequencing data. Variants were automatically classified as potential causal variants based on the following considerations derived from the American College of Medical Genetics and Genomics (ACMG) guidelines[^11^](#cti21138-bib-0011){ref-type="ref"}, [^12^](#cti21138-bib-0012){ref-type="ref"}: (1) the association between the variation‐affected gene and the individual's phenotypes; (2) the inheritance model of relevant genes; (3) the zygosity of variants; and (4) whether a compound heterozygous event had occurred. Variations that satisfied these criteria were diagnosed as pathogenic variations.

In general, approximately 150 SNVs were classified as candidate variants for each patient. Lists of variants were then further manually prioritised based on phenotypic information and subjected to Sanger sequencing. All candidate disease‐causing variants were additionally confirmed via Sanger sequencing. Moreover, CNV analyses were performed for whom no causal SNVs or indels could be identified; 0--2 potential CNVs were detected in each patient. All candidate disease‐causing CNVs were confirmed using internally controlled multiplex PCR amplification. In addition, clinical data or functional test results are consistent with the phenotype of variants. Finally, 49 SNVs from 38 infants and 13 of the suspected exonic deletions from 13 infants were confirmed to be disease‐causing variants. A summary of the confirmed disease‐causing variants is shown in [Supplementary table 1](#cti21138-sup-0001){ref-type="supplementary-material"}.

Diagnostic efficiency {#cti21138-sec-0009}
---------------------

Fifty‐one individuals (2.1%, 51/2392) had disease‐related PID gene mutations detected using NGS ([Supplementary table 1](#cti21138-sup-0001){ref-type="supplementary-material"}). According to the PID classification,[^4^](#cti21138-bib-0004){ref-type="ref"} seven types of immunodeficiency diseases were found: four cases were immunodeficiencies affecting cellular and humoral immunity; 25 cases were combined immunodeficiencies with associated or syndromic features; three cases were predominantly antibody deficiencies; six cases involved diseases of immune dysregulation; nine cases were congenital defects of phagocyte number or function; three cases were defects in intrinsic and innate immunity; and one case was an autoinflammatory disorder (Figure [2](#cti21138-fig-0002){ref-type="fig"}). No case consisted of complement deficiencies or phenocopies of inborn errors of immunity in the cohort. Forty‐seven (47/1680, 2.80%) patients with PID were identified in patients requiring ICU support, and 4 (4/712, 0.56%) were identified in patients not requiring ICU support, and there was a significant difference (*P* \< 0.01).

![Primary immunodeficiency diseases types, disease‐causing genes and the number of cases identified in the infant cohort in this study.](CTI2-9-e1138-g002){#cti21138-fig-0002}

Among the diagnosed PIDs, the most common type of disease was combined immunodeficiencies with associated or syndromic features, which accounted for almost one‐half (49%, 25/51) of all diagnosed PIDs. DiGeorge syndrome was particularly common. Thirteen patients were diagnosed with DiGeorge Syndrome, seven patients had congenital cardiac disease, and two had hypocalcaemia. The top 10 specific disease‐causing genes are shown in Figure [3](#cti21138-fig-0003){ref-type="fig"}.

![Top 10 primary immunodeficiency diseases‐causing genes and the number of cases in the infant cohort in this study.](CTI2-9-e1138-g003){#cti21138-fig-0003}

T‐cell receptor excision circles/kappa‐deleting recombination excision circles (TRECs/KRECs) detection {#cti21138-sec-0010}
------------------------------------------------------------------------------------------------------

T‐cell receptor excision circles/kappa‐deleting recombination excision circles (TRECs/KRECs) detection is widely used for newborn screening, and we used the detection for all of the above‐mentioned 51 patients. Lymphocytes from the positive patient were subjected to lymphocyte subset detection by flow cytometry. The results showed that 12 patients had decreased T cells (\< 1000 µL^−1^) and two patients had decreased B cells (\< 300 µL^−1^). The patients with decreased T cells included five with DiGeorge Syndrome, one with *CHD7* mutation, one with *ATM* mutation, one with *CD40LG* mutation, one with *IKBKG* mutation, one with *IL2RG* mutation, one with *LIG4* mutation and one with *RAG1* mutation. The two patients with decreased B cells had *BTK* mutation. This result indicates that only 14 patients could be identified with PIDs by TRECs/KRECs detection in the infant cohort.

Clinical management and treatment implications {#cti21138-sec-0011}
----------------------------------------------

The positive diagnostic results produced widespread effects on clinical management, resulting in the offering of appropriate treatment or changes in treatment and prompting the provision of appropriate genetic counselling. In this study, 51 patients (2.1%) were diagnosed with PIDs. After diagnosis, all patients received the corresponding treatment. Thirty‐five patients were cured or improved, including 30 patients who had specific therapy ([Supplementary table 1](#cti21138-sup-0001){ref-type="supplementary-material"}).

The diseases of patients with *IL2RG*, *LIG4* and *RAG1* gene mutations were confirmed by lymphocyte subsets and immunoglobulin detection. These patients had extremely low CD3^+^ T‐cell counts. The diagnosis of severe combined immunodeficiency (SCID) was clear. SCID has high mortality if not diagnosed in a timely manner. Haematopoietic stem cell transplantation (HSCT) is the way to cure this disease. The three patients with SCID received HSCT, and all were cured. A *CD40LG* mutation results in hyper‐IgM syndrome, one kind of CID. The one patient with the *CD40LG* mutation had CMV and BCG infections when they were diagnosed. The patient received HSCT after the infection was controlled, and he was cured.

Twenty‐five patients were diagnosed with combined immunodeficiencies with associated or syndromic features, including 13 patients with DiGeorge syndrome, three patients with CHARGE syndrome, four patients with Wiskott--Aldrich syndrome (WAS), three patients with ataxia‐telangiectasia, one patient with hyper‐IgE syndrome, and one patient with an *IKBKG* mutation. All four patients with WAS had platelets \< 100 × 10^9^ L^−1^ and received HSCT, two were cured, and two died. The three patients with ataxia‐telangiectasia received regular intravenous immunoglobulin (IVIG) therapy. The other eighteen patients received symptomatic treatment. Patients with DiGeorge syndrome or CHARGE syndrome still had occasional infections.

For the three patients with predominantly antibody deficiencies, two patients had *BTK* mutation, and one had *TNFRSF13B* mutation. Both patients with the *BTK* mutation had good prognoses with regular IVIG therapy. The patient with the *TNFRSF13B* mutation had severe pneumonia at 2 months old. Therefore, we included him in the study and detected the gene variants. Because he had normal immunoglobulin at that time, we followed this patient. When he was 8 months old, he had a Candida albicans infection and hypogammaglobulinaemia. And then, he received regular IVIG therapy.

Among the six patients with immune dysregulation diseases, three patients had *IL10RA* mutation, two patients had *SH2D1A* mutation, and one patient had *STXBP2* mutation. All three patients with *IL10RA* mutation had chronic diarrhoea when they were diagnosed and received HSCT, and two of these patients were cured. Among the two patients with *SH2D1A* mutation and one patient with *STXBP2* mutation, two patients died of severe EBV infection during the neonatal period, and one patient was cured using HSCT.

In addition, three patients had *ELANE* mutation, one patient had *CSF3R* mutation, and one patient had *VPS13B* mutation. The neutrophil count was regularly monitored. One patient with severe neutropenia as a result of *ELANE* mutation received HSCT and was cured. Three patients were diagnosed with chronic granulomatous disease (CGD) because of *CYBB* or *CYBA* mutation; one patient received HSCT, and the other two patients received antifungal drugs and interferon‐γ therapy. The patient with *ITGB2* mutation was cured by HSCT.

Two patients with *IL12RB1* mutation received interferon‐γ therapy. They are living well. After one patient with *STAT1* mutation was found, we performed functional analysis. The mutation was confirmed to be a gain‐of‐function mutation. Then, the patient received antifungal drugs. For the patients with autoinflammatory disorders, including one patient with *NOD2* mutation, symptomatic treatment was administered.

NGS costs {#cti21138-sec-0012}
---------

The cost of NGS was approximately US\$280 per sample. It is clear that NGS is a more rapid alternative to Sanger sequencing with respect to reagent costs for all genes. In addition, much greater labour is required for classical Sanger sequencing than for NGS.

Discussion {#cti21138-sec-0013}
==========

Primary immunodeficiency diseases constitute a group of highly heterogeneous genetic disorders. Approximately 3110 genes may potentially cause PIDs based on their biological functions and human gene connectome analysis.[^13^](#cti21138-bib-0013){ref-type="ref"} However, the prevalence of various forms of PIDs is likely underestimated.[^14^](#cti21138-bib-0014){ref-type="ref"} There are currently more than 400 forms of PIDs defined by the International Union of Immunological Societies (IUIS).[^1^](#cti21138-bib-0001){ref-type="ref"}, [^2^](#cti21138-bib-0002){ref-type="ref"} The main reason that PIDs cannot be identified earlier is a lack of specific symptoms during early infancy.

Gene discovery and an understanding of the molecular bases of PIDs are essential starting points for determining a molecular diagnosis and providing genetic counselling[^15^](#cti21138-bib-0015){ref-type="ref"} and may provide clues to the development of new therapeutic approaches for different diseases. In recent years, several studies have investigated the clinical efficacy of gene sequencing for different PIDs.[^16^](#cti21138-bib-0016){ref-type="ref"}, [^17^](#cti21138-bib-0017){ref-type="ref"}, [^18^](#cti21138-bib-0018){ref-type="ref"}, [^19^](#cti21138-bib-0019){ref-type="ref"}, [^20^](#cti21138-bib-0020){ref-type="ref"}, [^21^](#cti21138-bib-0021){ref-type="ref"}, [^22^](#cti21138-bib-0022){ref-type="ref"} These studies focused on patients with specific PID phenotypes.

In our study, hospitalised infants without clear PID phenotypes were investigated. We identified disease‐causing genes in 51 out of 2392 patients during early life. This proportion is an encouraging diagnostic rate of approximately 2.1% from an infant cohort. Our results indicated that the prevalence of PID is underestimated. Interestingly, there is a difference in the rate of PID identification in children of different severities. More severe diseases result in a higher rate of PID identification. This result indicated that we should consider the possibility of PID for patients with severe infection.

The phenotyping of PID patients often requires detailed, functional immunological assays to determine specific defects in cellular functions.[^23^](#cti21138-bib-0023){ref-type="ref"} Many patients may be misdiagnosed because of a lack of specific symptoms. Neonatal TRECs/KRECs screening is widely used for early PID diagnosis.[^24^](#cti21138-bib-0024){ref-type="ref"}, [^25^](#cti21138-bib-0025){ref-type="ref"}, [^26^](#cti21138-bib-0026){ref-type="ref"} This is very useful for the identification of immunodeficiencies that affect the numbers of T and B cells. However, almost half of the patients in our cohort had combined immunodeficiencies with associated or syndromic features. Only one quarter had decreased T cells or B cells. Routine TRECs/KRECs screening could miss a PID diagnosis. Our results showed the clinical importance of genetic investigation in infants with infection during early life.

Definitive diagnosis is beneficial for patients and their families in various ways, including allowing for identification of potential treatments, recognition of the risk of transmission in subsequent pregnancies, and provision of anticipatory guidance and prognosis. In our study, approximately 60% of patients (30/51) received specific treatments after being diagnosed with PID and consequently had better prognoses. If they had not been promptly diagnosed, most of these patients would have died, especially the SCID patients. The turnaround time of NGS was 2 weeks. Some PIDs can be identified quickly by functional testing. For example, we can identify some patients with SCID by flow cytometry. However, some patients do not have specific characteristic immune phenotypes. For these patients, NGS is needed. Even for patients with specific immune phenotypes, the genetic diagnosis is still useful. As such, our genetic test might reasonably be offered as a first‐line genetic assessment for early life infants who have infections in clinics. This study highlights advantages of NGS for PID screening in early life infants. In particular, the cost of sequencing is only US\$280 per sample. This expense is conducive to the popularisation of the tested approach, especially in developing countries.

In conclusion, this study shows the clinical applications and benefits of genetic testing in the clinical management of early life infants. Such testing is extremely useful for the early identification of PIDs. This study not only highlighted the potential of NGS to rapidly provide molecular diagnoses of PIDs but also indicated that the prevalence of PIDs is underestimated. With broader use, this approach has the potential to alter clinical strategies in early life infants.

Methods {#cti21138-sec-0014}
=======

This study was approved by the ethics committee of the Children's Hospital of Fudan University. Written informed consent was obtained from the parents of all of the patients. The methods were conducted in accordance with the approved guidelines.

Patients and sample preparation {#cti21138-sec-0015}
-------------------------------

To explore the use of NGS in the early identification of PIDs, patients who met the following criteria were included in the study from November 2015 to April 2018. Inclusion criteria were as follows: (1) age \<3 months and (2) hospitalised for infectious diseases, regardless of the extent and location of the infection or abnormal routine blood test (white blood cells \< 4000 µL^−1^ or \> 20 000 µL^−1^; or platelets \< 100 × 10^9^ L^−1^).

After the collection of 2 mL of EDTA‐anticoagulated blood, DNA was extracted from peripheral blood mononuclear cells, which were isolated using lymphocyte separation medium (Beyotime Biotechnology, Shanghai, China).

NGS and variation analysis {#cti21138-sec-0016}
--------------------------

Fragments of patients' genomic DNA were enriched for panel sequencing using the Agilent ClearSeq Inherited Disease panel kit. The panel included all known PID‐associated genes[^27^](#cti21138-bib-0027){ref-type="ref"} at that time. The methods for NGS and variation analysis have been reported previously.[^28^](#cti21138-bib-0028){ref-type="ref"} Enriched DNA samples were indexed and sequenced on a HiSeq2000 sequencer (Illumina, San Diego, CA, USA) using standard protocols in a Clinical Laboratory Improvement Amendments (CLIA)‐compliant sequencing laboratory at WuXi NextCODE (CLIA ID 99D2064856). Sequencing provided at least 50 million 125‐bp paired‐end reads for each sample.

Reads were mapped to the human reference genome hg19 using Burrows‐Wheeler Aligner (BWA). The average coverage sequencing depth for the official targets was at least 180× and was higher than 20× for \> 99% of the target region. Variants were called in accordance with the gold standard of the GATK Best Practices. Deleterious mutations and novel variants detected using NGS were confirmed via Sanger sequencing. A coverage‐based algorithm, CANOES, was used to detect large exonic deletions and duplications. Based on the validation results of the array comparative genomic hybridisation (CGH) experiments, ratios \< 0.65 and \> 1.35 were scored as deletions and duplications, respectively. All positive calls were further investigated and confirmed via Sanger sequencing or quantitative polymerase chain reaction (qPCR). The turnaround time of the entire experimental process was 2 weeks.

Management of patients diagnosed with PIDs {#cti21138-sec-0017}
------------------------------------------

Once a mutation in a PID‐associated gene was found in patients, functional testing associated with this mutation will be finished. The patients were diagnosed based on clinical symptoms, genetic data and functional testing. Then, the patients received corresponding management and follow‐up treatments.
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